AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AROA BIOSURGERY LTD

0.570

-0.010-1.72%

Volume:175.56K

Turnover:100.58K

Market Cap:196.67M

PE:53.08

High:0.580

Open:0.580

Low:0.570

Close:0.580

52wk High:0.800

52wk Low:0.495

Shares:345.03M

Float Shares:258.64M

Volume Ratio:0.70

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.011

EPS(LYR):0.013

ROE:4.86%

ROA:3.09%

PB:2.37

PE(LYR):44.19

Loading ...

Overview Company News Filings

Accelerant Launches ARX Consortium to Boost Partnership With Lloyd's of London

MT Newswires Live

3 Insurance Stocks Retail Investors Are Watching For Steady Rates

Simply Wall St.

A Look At Aroa Biosurgery’s Valuation After Its Profit Turnaround In Full Year 2026 Results

Simply Wall St.

ASX Penny Stocks Spotlight Aroa Biosurgery And Two More Top Picks

Simply Wall St.

Aroa Biosurgery (ASX:ARX) TTM Profitability Emerges While 1H Loss Tests Bullish Growth Narrative

Simply Wall St.

BUZZ-Australia-listed Aroa Biosurgery climbs as annual earnings beat guidance

BRIEF-Aroa Biosurgery Posts Adjusted EBITDA Of NZ$12.6 Million

Aroa Biosurgery Sees FY27 Normalised Ebitda of Nz$8-11 Mln

THOMSON REUTERS

Aroa Biosurgery FY Product Gross Margin 85.5%

THOMSON REUTERS

Aroa Biosurgery FY Adjusted Operating Expenses Nzd 82.5 Million

THOMSON REUTERS

A Look At Accelerant Holdings’ Valuation After Recent Share Price Momentum

Simply Wall St.

Accelerant Shows Strong Early Traction as Buybacks Increase, RBC Says

MT Newswires Live

Accelerant Q1 Adjusted Earnings, Revenue Rise

MT Newswires Live

Earnings Flash (ARX) Accelerant Posts Q1 Adjusted EPS $0.17, vs. FactSet Est of $0.16

MT Newswires Live

BUZZ-Aroa Biosurgery climbs as prelim annual results beat outlook

BRIEF-Aroa Biosurgery Posts FY26 Prelim Total Revenue Of NZ$104 Million

Aroa Biosurgery - FY26 Prelim Total Revenue of Nz$104 Mln

THOMSON REUTERS

Analysts Expect Breakeven For Aroa Biosurgery Limited (ASX:ARX) Before Long

Simply Wall St.

Accelerant Names Linda Huber CFO

MT Newswires Live

Aroa Biosurgery says Symphony diabetic foot ulcer trial meets primary endpoint in preliminary readout

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ARX.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ARX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ARX.AU\",,,,,undefined,":{"symbol":"ARX.AU","market":"AU","secType":"STK","nameCN":"AROA BIOSURGERY LTD","latestPrice":0.57,"timestamp":1787292720000,"preClose":0.58,"halted":0,"volume":175560,"delay":0,"changeRate":-0.017241379310344845,"nameEN":"AROA BIOSURGERY LTD","floatShares":258636705,"shares":345033235,"eps":0.010739,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"08-21 16:12:00 AEST","open":0.58,"high":0.58,"low":0.57,"amount":100584,"amplitude":0.017241,"askPrice":0.59,"askSize":100000,"bidPrice":0.565,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":0.010739,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.58,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.699252234715865,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ARX.AU","preClose":0.58,"auctionPrice":0.58,"auctionVolume":3255,"auction":3,"marketStatus":"盘后竞价","timestamp":1787206200332}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ARX.AU\",,,,,undefined,":{"symbol":"ARX.AU","floatShares":258636705,"roa":"3.09%","roe":"4.86%","lyrEps":0.0129,"volumeRatio":0.699252234715865,"shares":345033235,"dividePrice":0,"high":0.58,"amplitude":0.017241,"preClose":0.58,"low":0.57,"week52Low":0.495,"pbRate":"2.37","psRate":"2.27","week52High":0.8,"institutionHeld":0,"latestPrice":0.57,"committee":-0.818182,"eps":0.010739,"divideRate":0,"volume":175560,"delay":0,"ttmEps":0.010739,"open":0.58,"prevYearClose":0.74,"prevWeekClose":0.6,"prevMonthClose":0.57,"prevQuarterClose":0.595,"fiveDayClose":0.6,"twentyDayClose":0.56,"sixtyDayClose":0.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-05-26","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1779753600000,"name":null,"time":"Pre-MKt","dateTimestamp":1779717600000,"actualEps":null},{"date":"2025-11-24","symbol":"ARX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763938800000,"name":null,"time":"","dateTimestamp":1763902800000,"actualEps":null},{"date":"2025-10-30","symbol":"ARX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761778800000,"name":null,"time":"","dateTimestamp":1761742800000,"actualEps":null},{"date":"2025-10-15","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1760482800000,"name":null,"time":"Pre-MKt","dateTimestamp":1760446800000,"actualEps":null},{"date":"2025-07-28","symbol":"ARX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1753660800000,"name":null,"time":"","dateTimestamp":1753624800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARX.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648652371","title":"Accelerant Launches ARX Consortium to Boost Partnership With Lloyd's of London","url":"https://stock-news.laohu8.com/highlight/detail?id=2648652371","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648652371?lang=en_us&edition=fundamental","pubTime":"2026-07-02 03:33","pubTimestamp":1782934430,"startTime":"0","endTime":"0","summary":"Accelerant Holdings (ARX) said Wednesday it launched the ARX Consortium, backed by seven Lloyd's of London, syndicates, to bolster its partnership with the specialty insurance market.Price: 12.70, Change: +0.98, Percent Change: +8.36","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARX.AU","ARX","BK4173","LU1861220207.SGD","LU1861217088.USD","LU2360107671.USD","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535470","title":"3 Insurance Stocks Retail Investors Are Watching For Steady Rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535470","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647535470?lang=en_us&edition=fundamental","pubTime":"2026-06-30 14:18","pubTimestamp":1782800306,"startTime":"0","endTime":"0","summary":"With the US Supreme Court reaffirming the Federal Reserve’s independence while handing the White House more control over key regulators like the SEC and FTC, large financial stocks sit right on the fault line of these changes. Rate policy stability, combined with more unpredictable regulatory shifts, can reshape how banks, insurers, brokers, and asset managers are priced and policed. This article focuses on three large cap financial sector stocks from our screener that appear positively...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/7211000-choice1-main-header/1585188082493","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7211000-choice1-main-header/1585188082493"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/insurance/nyse-ryan/ryan-specialty-holdings/news/3-insurance-stocks-retail-investors-are-watching-for-steady","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/insurance/nyse-ryan/ryan-specialty-holdings/news/3-insurance-stocks-retail-investors-are-watching-for-steady","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4173","FIGR","LU1861220207.SGD","BK7067","LU2360107671.USD","BK4539","ARX.AU","LU1861217088.USD","BK4166","RYAN","ARX","FGRU","BK4211","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639644482","title":"A Look At Aroa Biosurgery’s Valuation After Its Profit Turnaround In Full Year 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2639644482","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639644482?lang=en_us&edition=fundamental","pubTime":"2026-05-29 13:06","pubTimestamp":1780031161,"startTime":"0","endTime":"0","summary":"Why Aroa Biosurgery’s latest earnings matter for ASX:ARX holders\nAroa Biosurgery (ASX:ARX) has drawn fresh attention after reporting full year 2026 results, with sales of NZ$103.85 million and a shift from a net loss to a NZ$4.68 million profit.\nSee our latest analysis for Aroa Biosurgery.\nThe latest earnings announcement follows a strong short-term performance, with a 7 day share price return of 13.33% and a 30 day share price return of 21.43%, even though the share price is down 6.85% year...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/a-look-at-aroa-biosurgerys-valuation-after-its-profit-turnar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/a-look-at-aroa-biosurgerys-valuation-after-its-profit-turnar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638063415","title":"ASX Penny Stocks Spotlight Aroa Biosurgery And Two More Top Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2638063415","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638063415?lang=en_us&edition=fundamental","pubTime":"2026-05-28 03:02","pubTimestamp":1779908547,"startTime":"0","endTime":"0","summary":"As the Australian market holds steady, waiting for crucial inflation data, investors are keeping a close eye on potential opportunities amidst global economic shifts. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or newer companies with potential for growth and value. By focusing on those with strong financials and clear growth trajectories, investors can uncover promising opportunities in this unique segment of the market.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-penny-stocks-spotlight-aroa-biosurgery-and-two-more-top","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-penny-stocks-spotlight-aroa-biosurgery-and-two-more-top","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067","DUR.AU","SRG.AU","BK7055"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638650183","title":"Aroa Biosurgery (ASX:ARX) TTM Profitability Emerges While 1H Loss Tests Bullish Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2638650183","media":"Simply Wall St.","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638650183?lang=en_us&edition=fundamental","pubTime":"2026-05-27 18:07","pubTimestamp":1779876474,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery (ASX:ARX) has just reported FY 2026 first half revenue of NZ$44.9 million, with a reported loss of NZ$1.3 million and basic EPS of NZ$0.0038 loss, while the trailing twelve months show revenue of NZ$103.9 million and net income of NZ$4.7 million translating to basic EPS of NZ$0.0135. Over recent periods the company has seen revenue move from NZ$39.2 million in 1H FY 2025 to NZ$45.5 million in 2H FY 2025, alongside EPS shifting from NZ$0.0096 loss to NZ$0.0015 loss. Together,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-ttm-profitability-emerges-while-1h-lo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-ttm-profitability-emerges-while-1h-lo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638363560","title":"BUZZ-Australia-listed Aroa Biosurgery climbs as annual earnings beat guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2638363560","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638363560?lang=en_us&edition=fundamental","pubTime":"2026-05-26 12:15","pubTimestamp":1779768946,"startTime":"0","endTime":"0","summary":"BUZZ-Australia-listed Aroa Biosurgery climbs as annual earnings beat guidance** Shares of Aroa Biosurgery ARX.AX rise as much as 3.2% to A$0.64, their highest level since May 11** Stock logs largest intraday pct gain since May 22** New Zealand-based soft-tissue regeneration products maker logs FY26 normalised EBITDA of NZ$11 million  vs guidance of NZ$5 million to NZ$8 million** Co books 54% myriad sales growth in FY26** More than 608,000 shares change hands, 2.8 times the 30-day average** Stock down 15.5% YTD, including the day's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4N42307Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638569387","title":"BRIEF-Aroa Biosurgery Posts Adjusted EBITDA Of NZ$12.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2638569387","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638569387?lang=en_us&edition=fundamental","pubTime":"2026-05-26 09:11","pubTimestamp":1779757876,"startTime":"0","endTime":"0","summary":"BRIEF-Aroa Biosurgery Posts Adjusted EBITDA Of NZ$12.6 MillionMay 26  - Aroa Biosurgery Ltd ARX.AX:FY ADJUSTED EBITDA NZD 12.6 MILLIONFY PRODUCT REVENUE NZD 103.9 MILLIONFY PRODUCT GROSS MARGIN 85.5%AROA BIOSURGERY FY GROSS PROFIT NZD 88.8 MILLIONAROA BIOSURGERY FY ADJUSTED OPERATING EXPENSES NZD 82.5 MILLIONAROA BIOSURGERY SEES FY27 TOTAL REVENUE GUIDANCE OF NZ$115-125 MILLIONAROA BIOSURGERY SEES FY27 NORMALISED EBITDA OF NZ$8-11 MILLIONFurther company coverage: ARX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nPLXC60A8A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638756869","title":"Aroa Biosurgery Sees FY27 Normalised Ebitda of Nz$8-11 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2638756869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638756869?lang=en_us&edition=fundamental","pubTime":"2026-05-26 06:49","pubTimestamp":1779749358,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nPLXC60A8A:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638568690","title":"Aroa Biosurgery FY Product Gross Margin 85.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638568690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638568690?lang=en_us&edition=fundamental","pubTime":"2026-05-26 06:49","pubTimestamp":1779749358,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nPLXC60A8A:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638568616","title":"Aroa Biosurgery FY Adjusted Operating Expenses Nzd 82.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2638568616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638568616?lang=en_us&edition=fundamental","pubTime":"2026-05-26 06:49","pubTimestamp":1779749358,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nPLXC60A8A:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636346864","title":"A Look At Accelerant Holdings’ Valuation After Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2636346864","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636346864?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:30","pubTimestamp":1779215445,"startTime":"0","endTime":"0","summary":"Why Accelerant Holdings is on investors’ radar\nAccelerant Holdings (ARX) has drawn attention after recent trading, with the stock closing at $15.91 and posting gains over the past week, month, and past 3 months that stand out in a mixed insurance sector.\nSee our latest analysis for Accelerant Holdings.\nThe recent 3.04% 1-day share price return and 51.81% 90-day share price return suggest strong short-term momentum, while the 1.92% year-to-date share price return paints a more measured...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/7211000-choice2-main-header/1585187169399","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7211000-choice2-main-header/1585187169399"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/insurance/nyse-arx/accelerant-holdings/news/a-look-at-accelerant-holdings-valuation-after-recent-share-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/insurance/nyse-arx/accelerant-holdings/news/a-look-at-accelerant-holdings-valuation-after-recent-share-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","ARX.AU","LU1861220207.SGD","LU2360107671.USD","ARX","LU1861217088.USD","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635354670","title":"Accelerant Shows Strong Early Traction as Buybacks Increase, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2635354670","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635354670?lang=en_us&edition=fundamental","pubTime":"2026-05-15 23:34","pubTimestamp":1778859241,"startTime":"0","endTime":"0","summary":"Accelerant Holdings  continues to execute on its business plan in its first few public quarters and is using its current share price levels to repurchase stock rapidly, RBC Capital Markets said Thursday in a report.RBC raised its 2026 adjusted EPS estimate to $0.70 from $0.58, and its 2027 estimate to $1 from $0.80, reflecting improved profitability expectations in H2 and in 2027, along with significant buybacks.The firm also increased its adjusted EBITDA estimates to $289.3 million for 2026 from $275.9 million, and to $379 million for 2027 from $376.2 million.Accelerant is an insurance holding company that operates a data-driven risk exchange connecting specialty underwriters with risk-capital partners.With Accelerant disclosing $52 million of Q2 repurchases in addition to $11 million in Q1 buybacks, RBC now models full utilization of the company's $200 million authorization by 2026 and projects an incremental $100 million of buybacks in 2027.RBC maintained its outperform rating on Ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1861220207.SGD","LU2360107671.USD","BK4173","BK7067","ARX","LU1861217088.USD","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635275631","title":"Accelerant Q1 Adjusted Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2635275631","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635275631?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:51","pubTimestamp":1778705481,"startTime":"0","endTime":"0","summary":"Accelerant  reported Q1 adjusted earnings late Wednesday of $0.17 per diluted share, up from $0.08 a year earlier.Analysts polled by FactSet expected $0.16.Revenue for the quarter ended March 31 rose to $273.3 million from $178 million a year earlier.Analysts surveyed by FactSet expected $245 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4173","BK7067","ARX.AU","LU1861217088.USD","LU1861220207.SGD","LU2360107671.USD","ARX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635755472","title":"Earnings Flash (ARX) Accelerant Posts Q1 Adjusted EPS $0.17, vs. FactSet Est of $0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2635755472","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635755472?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:38","pubTimestamp":1778704708,"startTime":"0","endTime":"0","summary":"Earnings Flash (ARX) Accelerant Posts Q1 Adjusted EPS $0.17, vs. FactSet Est of $0.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARX.AU","ARX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631956501","title":"BUZZ-Aroa Biosurgery climbs as prelim annual results beat outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2631956501","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631956501?lang=en_us&edition=fundamental","pubTime":"2026-04-30 14:02","pubTimestamp":1777528945,"startTime":"0","endTime":"0","summary":"BUZZ-Aroa Biosurgery climbs as prelim annual results beat outlook** Shares of Aroa Biosurgery ARX.AX rise as much as 21.8% to A$0.670, their biggest gain since late July 2020** Soft-tissue regeneratio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nL6N41D0FI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631408574","title":"BRIEF-Aroa Biosurgery Posts FY26 Prelim Total Revenue Of NZ$104 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631408574","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631408574?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:52","pubTimestamp":1777513937,"startTime":"0","endTime":"0","summary":"BRIEF-Aroa Biosurgery Posts FY26 Prelim Total Revenue Of NZ$104 MillionApril 30 (Reuters) - Aroa Biosurgery Ltd ARX.AX:FY26 PRELIM TOTAL REVENUE OF NZ$104 MILLIONFY26 PRELIM NORMALISED EBITDA OF NZ$11-12 MILLIONFurther company coverage: ARX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41C1R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631344520","title":"Aroa Biosurgery - FY26 Prelim Total Revenue of Nz$104 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2631344520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631344520?lang=en_us&edition=fundamental","pubTime":"2026-04-30 06:24","pubTimestamp":1777501478,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627668814","title":"Analysts Expect Breakeven For Aroa Biosurgery Limited (ASX:ARX) Before Long","url":"https://stock-news.laohu8.com/highlight/detail?id=2627668814","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627668814?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:04","pubTimestamp":1776110647,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Aroa Biosurgery Limited's ( ASX:ARX ) business as it appears the company...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/analysts-expect-breakeven-for-aroa-biosurgery-limited-asxarx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/analysts-expect-breakeven-for-aroa-biosurgery-limited-asxarx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK4173","BK7067","LU1861217088.USD","LU1861220207.SGD","ARX","LU2360107671.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624306545","title":"Accelerant Names Linda Huber CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2624306545","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624306545?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:26","pubTimestamp":1774988818,"startTime":"0","endTime":"0","summary":"Accelerant (ARX) said Tuesday it appointed Linda Huber as chief financial officer following a previously announced transition.Huber was most recently the executive vice president and CFO of FactSet Research Systems (FDS) from 2021 to 2024, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4585","BK4112","LU1861220207.SGD","LU2210150020.SGD","LU1861217088.USD","LU2360107671.USD","FDS","ARX","BK4173","BK4567","BK4588","LU2210149790.SGD","LU2095319765.USD","ARX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623362624","title":"Aroa Biosurgery says Symphony diabetic foot ulcer trial meets primary endpoint in preliminary readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2623362624","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623362624?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:00","pubTimestamp":1774836001,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery completed randomized controlled trial of Symphony skin substitute in chronic Wagner grade 1–2 diabetic foot ulcers, with preliminary read-out indicating primary endpoint met.Primary endpoint measured proportion of ulcers healed within 12 weeks versus standard-of-care dressings.Trial enrolled up to 150 patients across multiple US sites, with weekly treatment until healing or up to 12 weeks.Final analysis pending, with full results scheduled for publication in coming months.Management expects published data to strengthen reimbursement positioning for Symphony under tighter future evidence standards.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2dWT75:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":43,"code":"91000000","status":"200"}]}}